GRAIL is trading at $124.89, up 4.84% on November 6, 2026, rebounding after a 17.08% fall on November 5; no fresh company-specific announcement or reliable report explains the morning gain.
- Recent reporting points to Q3 revenue below expectations and reduced 2026 Galleri revenue-growth guidance, offering negative context rather than a clear explanation.
- Broader markets showed signs of recovering from Thursday’s selloff, but biotech-sector weakness does not explain GRAIL’s rise.